A flow cytometry-based digital immunoassay method for detecting low-abundance analytes using engineered bacteriophages.

By displaying horseradish peroxidase and streptavidin on bacteriophages, the limitations of natural enzymes in immunoassays are overcome, enabling the detection of low-abundance substances with high sensitivity, low cost, and good stability.

CN120594817BActive Publication Date: 2026-11-17NANJING RENMAI BIOTECHNOLOGY CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202510782626.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-06-12
Publication Date
2026-11-17
Estimated Expiration
2045-06-12

AI Technical Summary

Technical Problem

Existing immunoassay methods are inadequate for detecting minute differences between samples and low concentrations of analytes. Natural enzymes suffer from low activity and low sensitivity as monomers, while polymers of naturally occurring enzymes exhibit poor stability, high cost, and difficulty in standardized preparation.

Method used

Using engineered phage display technology, horseradish peroxidase and streptavidin are expressed on phages. By replacing natural enzymes with phage display technology, stable and controllable polymers are prepared to achieve signal amplification and detection.

Benefits of technology

It improves enzyme activity and sensitivity, reduces costs, ensures polymer stability and minimal batch-to-batch variation, and facilitates standardized preparation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120594817B_ABST
    Figure CN120594817B_ABST
Patent Text Reader

Abstract

This invention discloses a flow cytometry digital immunoassay method based on engineered bacteriophages for detecting low-abundance analytes. In this method, the analyte is labeled with engineered bacteriophages, and tyrosine and fluorescent materials bind to the phages, amplifying the analyte signal and ultimately determining the analyte. By using engineered bacteriophages instead of natural enzymes, this invention first solves the problems of low monomeric enzyme activity, low sensitivity, and difficulty in forming stable and controllable polymers inherent in natural enzymes. Secondly, it addresses the issues of poor stability, large batch-to-batch variation, high cost, and difficulty in standardized and stable preparation of polymers in polymerically coupled natural enzymes. Ultimately, this method achieves high enzyme activity and sensitivity, good stability, small batch-to-batch variation, low cost, and easy standardized and stable preparation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biological detection technology, specifically relating to a flow cytometry digital immunoassay method based on engineered bacteriophages for detecting low-abundance analytes. Background Technology

[0002] The systematic and precise quantitative detection of relevant biomarkers provides a necessary diagnostic foundation for the diagnosis, detection, and treatment of diseases. Among existing methods for detecting biomarkers, immunoassay is one of the most commonly used and has been widely applied in clinical testing. Immunoassay is based on the high specificity of antigen-antibody interactions and combines detection methods such as radiolabeling, enzyme catalysis, fluorescence, and chemiluminescence. However, existing methods are insufficient for detecting minute differences between samples (i.e., high resolution) and low concentrations of analytes (i.e., low detection limits), while using as few biological samples as possible.

[0003] Digital enzyme-linked immunosorbent assay (ELISA) can achieve absolute counting by reading the signals of individual protein molecules, thus exhibiting extremely high sensitivity and attracting widespread attention. However, the natural enzymes used in current signal amplification methods suffer from drawbacks such as low monomeric enzyme activity, low sensitivity, and difficulty in forming stable and controllable polymers. While polymer-coupled natural enzyme polymers offer high sensitivity, they also suffer from inherent disadvantages such as poor stability, large batch-to-batch variability in raw materials, high cost, and difficulty in standardizing and scalable preparation of polymers, thus limiting their further application in immunoassays. Finding substances with high enzyme activity, high specificity, high sensitivity, high biosafety, low cost, and easy standardization to replace natural enzymes has become a pressing problem for those skilled in the art. Phage display technology involves inserting the DNA sequence of a foreign protein or polypeptide into an appropriate position in the phage coat protein structural gene. This invention uses phage display technology to express horseradish peroxidase and streptavidin on engineered phages, solving the problems of existing technologies. Summary of the Invention

[0004] Purpose of the Invention: To overcome the shortcomings of existing technologies, this invention provides a flow cytometry digital immunoassay method based on engineered phages for detecting low-abundance analytes. Specifically, it is a method for detecting low-abundance analytes (<0.1 pg / mL) based on phage display technology. By replacing the commonly used natural enzymes with engineered phages, the invention first solves the problems of low monomeric enzyme activity, low sensitivity, and difficulty in forming stable and controllable polymers in natural enzymes. Secondly, it solves the problems of poor stability, large batch-to-batch variation of raw materials, high cost, and difficulty in standardizing and stabilizing the preparation of polymers from polymerically coupled natural enzymes. Ultimately, it achieves the goals of high enzyme activity and sensitivity, good stability, small batch-to-batch variation of raw materials, low cost, and easy standardization and stable preparation.

[0005] Technical solution: To achieve the above objectives, the technical solution adopted by this invention is as follows:

[0006] The first objective of this invention is to provide a flow cytometry digital immunoassay method based on engineered bacteriophages for detecting low-abundance analytes, comprising the following steps:

[0007] S1. Preparation of carrier particles coated with the first capturing substance: coating the first capturing substance onto the carrier particles;

[0008] S2. Preparation of labeled second capture substance: The second capture substance is labeled with biotin or single-display peroxidase engineered bacteriophage to obtain labeled second capture substance; the first capture substance and the second capture substance are independently substances that specifically bind to the analyte;

[0009] S3. Binding of the analyte and the captured substance: The carrier particle coated with the first captured substance, the analyte sample, and the labeled second captured substance are incubated to obtain the third binding complex.

[0010] S4. Signal amplification: Add the label and reaction substrate to the third binding complex, incubate, and obtain the test solution;

[0011] S5. Counting analysis: The test solution is tested, a standard curve is plotted based on the test results, and the content of the test substance in the test substance is calculated.

[0012] Optionally, in some embodiments of the present invention, in step S3, the binding of the analyte and the captured substance includes any one of the following a to f:

[0013] a. Binding of the analyte and the capture substance: The carrier particles coated with the first capture substance and the analyte sample are incubated at a first preset temperature to obtain the first binding complex; the second capture substance of the labeled peroxidase engineered phage is added, shaken and mixed, and incubated at a second preset temperature to obtain the third binding complex;

[0014] b. The carrier particles coated with the first capturing material, the sample to be tested, and the second capturing material of the labeled peroxidase-engineered bacteriophage are shaken and mixed, and incubated at a first preset temperature to obtain the third binding complex;

[0015] c. The carrier particles coated with the first capturing substance and the sample to be tested are incubated at a first preset temperature to obtain the first binding complex; the second capturing substance labeled with biotin is added and vortexed to mix, and incubated at a second preset temperature to obtain the second binding complex; the double-display peroxidase and affinity engineered phage are added and vortexed to mix, and incubated at a third preset temperature to obtain the third binding complex.

[0016] d. The carrier particles coated with the first capturing substance, the sample to be tested, the biotin-labeled second capturing substance, and the engineered phage with dual-display peroxidase and affinity are shaken and mixed, and incubated at a first preset temperature to obtain the third binding complex;

[0017] e. The carrier particles coated with the first capture substance and the sample to be tested are incubated at a first preset temperature to obtain the first binding complex; the double-display peroxidase and the engineered phage of the second capture substance are added, shaken and mixed, and incubated at a second preset temperature to obtain the third binding complex.

[0018] f. The carrier particles coated with the first capture substance, the sample to be tested, and the dual-display peroxidase are mixed with the engineered phage of the second capture substance by shaking and incubated at a first preset temperature to obtain the third binding complex.

[0019] Optionally, in some embodiments of the present invention, in step S4, the addition of the marker and the reactive substrate in the signal amplification step includes any one of the following:

[0020] Add fluorescently labeled tyrosine and a reaction substrate to the third binding complex, and incubate at a fourth preset temperature to obtain the test solution; or

[0021] Biotinylated tyrosine and a reaction substrate were added to the third binding complex, and the mixture was incubated at a fourth preset temperature to obtain the fourth binding complex.

[0022] In the fourth binding complex, a streptavidin-conjugated fluorescent label is added, and the mixture is incubated at the fifth preset temperature to obtain the test solution.

[0023] Optionally, in some embodiments of the present invention, in step S1, the coating method is selected from one of the following: NHS ester and EDC crosslinking method, glutaraldehyde crosslinking method, silanization method, and biotin-avidin coupling method.

[0024] Optionally, in some embodiments of the present invention, the carrier particles include magnetic microspheres.

[0025] Optionally, in some embodiments of the present invention, the particle size of the carrier particles is 0.10 to 50.0 μm, preferably 1 to 10 μm.

[0026] Optionally, in some embodiments of the present invention, the carrier particle concentration is 1×10⁻⁶. 4 Cells / mL~1×10 9 per mL.

[0027] Optionally, in some embodiments of the present invention, in step S1, the first capturing substance is one of an antibody, a receptor protein, a complementary nucleic acid, or an aptamer.

[0028] Optionally, in some embodiments of the present invention, the second capturing substance is one of an antibody, a receptor protein, a complementary nucleic acid, or an aptamer.

[0029] Optionally, in some embodiments of the present invention, in step S4, the marker is biotinylate or tyrosine conjugated with a fluorescent dye.

[0030] Optionally, in some embodiments of the present invention, the engineered phage is derived from one of the T4 phage display system, the single-stranded filamentous phage M13 display system, the λ phage display system, or the T7 phage display system.

[0031] Optionally, in some embodiments of the present invention, the engineered phage is derived from the phage display system: single-display peroxidase, double-display peroxidase and affinity engineered phage, or double-display peroxidase and second capture substance.

[0032] Optionally, in some embodiments of the present invention, the number of peroxidases, peroxidase-affinity agents, and peroxidases-second capture substances displayed on the bacteriophage is 200 to 800.

[0033] Optionally, in some embodiments of the present invention, the engineered phage is a T4 phage display system, the affinity compound is streptavidin, and the peroxidase is horseradish peroxidase.

[0034] Optionally, in some embodiments of the present invention, the number of horseradish peroxidases displayed on T4 phage is 800, the number of horseradish peroxidases and streptomycin affinity molecules is 600, and the number of horseradish peroxidases and second capture substances is 500.

[0035] Optionally, in some embodiments of the present invention, the reaction substrate includes one or more of benzoyl peroxide, tert-butanol peroxide, sodium persulfate, hydrogen peroxide, peracetic acid, and sodium peroxide, and the concentration of the reaction substrate is 0.1 mM to 10 mM.

[0036] Optionally, in some embodiments of the present invention, the test substance is one of antibody, small molecule compound, nucleic acid, vesicle, bacteria, virus, polypeptide, antigen or hapten.

[0037] Optionally, in some embodiments of the present invention, the sample to be tested is one of plasma, serum, whole blood, peripheral blood, cerebrospinal fluid, urine, environmental samples, etc.

[0038] Optionally, in some embodiments of the present invention, the first preset temperature is 25–37°C;

[0039] The second preset temperature is 25–37°C;

[0040] The third preset temperature is 25-37℃;

[0041] The fourth preset temperature is 4–60℃;

[0042] The fifth preset temperature is 25-37℃.

[0043] Beneficial effects: The flow cytometry digital immunoassay method based on engineered bacteriophages for detecting low-abundance analytes provided by this invention has the following advantages compared with existing technologies:

[0044] 1. The display type on the phage can be selected according to project needs, improving the convenience of this tool in flow cytometry digital immunoassay;

[0045] 2. Polymers are linked by chemical bonds, which makes them less controllable and less stable. In contrast, phages that exhibit peroxidase or capture substances remain as a whole, which makes them more stable and easier to standardize and prepare stably, thereby reducing batch-to-batch variation and lowering costs.

[0046] 3. Bacteriophages can display peroxidase alone, double peroxidase and affinity, or double peroxidase and a second capture substance, providing more options for different project requirements of reaction process. Attached Figure Description

[0047] Figure 1 This is a schematic diagram of the six reaction modes of the present invention.

[0048] Figure 2 It is a single-display peroxidase-engineered bacteriophage that does not combine the first two steps ( Figure 2 A) and the two steps before the merger ( Figure 2B) Reaction flow diagram.

[0049] Figure 3 It is the first three steps of the double-display peroxidase and affinity engineered phage that do not merge. Figure 3 A) and the three steps before the merger ( Figure 3 B) Reaction flow diagram.

[0050] Figure 4 It is a two-step process where the peroxidase and the second capture substance do not merge in the first two steps. Figure 4 A) and the two steps before the merger ( Figure 4 B) Reaction flow diagram.

[0051] Figure 5 They are magnetic microspheres with different codes.

[0052] Figure 6 This is a graph showing the correlation between particle size and signal-to-noise ratio.

[0053] Figure 7 This is a correlation graph between the coating ratio and the signal-to-noise ratio, that is, the coating ratio (wt%) of the interleukin-6 first capture antibody and the carrier particles.

[0054] Figure 8 This is a graph showing the correlation between the labeling ratio of the second capture antibody labeled with horseradish peroxidase-engineered phage and the signal-to-noise ratio, i.e., the labeling ratio (wt%) of the second capture antibody of interleukin-6 and the engineered phage labeled with horseradish peroxidase-engineered phage.

[0055] Figure 9 This is an accelerated stability curve at 37℃ for natural enzyme polymers and engineered bacteriophages.

[0056] Figure 10 This is the linear correlation curve plotted in Example 10. Detailed Implementation

[0057] This invention discloses a flow cytometry digital immunoassay method based on engineered bacteriophages for detecting low-abundance analytes. In this method, the analyte is labeled with engineered bacteriophages, and tyrosine and fluorescent materials bind to the phages, amplifying the analyte signal and ultimately determining the analyte. By using engineered bacteriophages instead of natural enzymes, this invention first solves the problems of low monomeric enzyme activity, low sensitivity, and difficulty in forming stable and controllable polymers inherent in natural enzymes. Secondly, it addresses the issues of poor stability, large batch-to-batch variation, high cost, and difficulty in standardized and stable preparation of polymers in polymerically coupled natural enzymes. Ultimately, this method achieves high enzyme activity and sensitivity, good stability, small batch-to-batch variation, low cost, and easy standardized and stable preparation.

[0058] Specifically, the present invention provides a flow cytometry digital immunoassay method for low-abundance analytes (<0.1 pg / mL) based on engineered bacteriophages, comprising:

[0059] Preparation of carrier particles coated with a first capturing substance: The first capturing substance is coated onto the carrier particles using a coating technique, wherein the first capturing substance can specifically bind to the analyte.

[0060] The labeling step of the second capture substance that can bind to the analyte: The second capture substance is labeled with biotin or single-display peroxidase engineered bacteriophage using labeling technology to obtain the labeled second capture substance;

[0061] The subsequent steps include the binding of the analyte and the captured substance, signal amplification, and counting analysis. The binding of the analyte and the captured substance is as follows: Figure 1 As shown, the present invention has 6 modes, which are described in detail below.

[0062] (1) Reaction Mode 1

[0063] Binding of the analyte and the capture substance: The carrier particles coated with the first capture substance and the analyte sample are incubated at a first preset temperature to obtain the first binding complex; the second capture substance of the labeled peroxidase engineered phage is added, shaken and mixed, and incubated at a second preset temperature to obtain the third binding complex;

[0064] (2) Reaction Mode 2

[0065] Binding of the analyte to the capture substance: The carrier particles coated with the first capture substance, the analyte sample, and the second capture substance of the labeled peroxidase-engineered bacteriophage are shaken and mixed, and incubated at a first preset temperature to obtain the third binding complex.

[0066] (3) Reaction Mode 3

[0067] Binding of the analyte and the capture substance: The carrier particle coated with the first capture substance and the analyte sample are incubated at a first preset temperature to obtain the first binding complex; the biotin-labeled second capture substance is added, shaken and mixed, and incubated at a second preset temperature to obtain the second binding complex; the double-display peroxidase and affinity engineered phage are added, shaken and mixed, and incubated at a third preset temperature to obtain the third binding complex.

[0068] (4) Reaction Mode 4

[0069] Binding of the analyte to the capture substance: The carrier particles coated with the first capture substance, the analyte, the biotin-labeled second capture substance, and the engineered phage with dual-display peroxidase and affinity are shaken and mixed, and incubated at a first preset temperature to obtain the third binding complex.

[0070] (5) Reaction Mode 5

[0071] Binding of the analyte and the capture substance: The carrier particles coated with the first capture substance and the analyte sample are incubated at a first preset temperature to obtain the first binding complex; the double-display peroxidase and the engineered phage of the second capture substance are added, shaken and mixed, and incubated at a second preset temperature to obtain the third binding complex;

[0072] (6) Reaction Mode 6

[0073] Binding of the analyte to the capture substance: The carrier particles coated with the first capture substance, the analyte sample, and the dual-display peroxidase are mixed with the engineered phage of the second capture substance by shaking and incubated at a first preset temperature to obtain the third binding complex.

[0074] Optionally, signal amplification includes the following steps: adding a label and a reaction substrate to the third binding complex described above, incubating, and obtaining the test solution.

[0075] Further, optionally, the addition of the marker and reactive substrate in the signal amplification step includes:

[0076] A fluorescent dye-labeled tyrosine and a reaction substrate are added to the third binding complex, and the mixture is incubated at a fourth preset temperature to obtain the test solution.

[0077] Optionally, adding the marker and reactant in the signal amplification step includes:

[0078] Biotinylated tyrosine and a reaction substrate were added to the third binding complex, and the mixture was incubated at a fourth preset temperature to obtain the fourth binding complex.

[0079] In the fourth binding complex, a streptavidin-conjugated fluorescent label is added, and the mixture is incubated at the fifth preset temperature to obtain the test solution.

[0080] Optionally, the counting analysis includes the following steps: testing the solution to be tested, plotting a standard curve based on the test results of the solution to be tested, and calculating the content of the analyte in the analyte.

[0081] Optionally, the coating technique includes direct coating or indirect coating.

[0082] Optionally, the coating technology is selected from one of the following: NHS ester and EDC crosslinking method, glutaraldehyde crosslinking method, silanization method, and biotin-avidin coupling method.

[0083] Optionally, the particle size of the carrier particles is 0.10 to 50.0 μm, and preferably, the particle size is 1 to 10 μm.

[0084] Optionally, the particle size of the carrier particles is a signal that distinguishes different particle groups.

[0085] Optionally, the signal that distinguishes different particle groups may also originate from the encoded fluorescent material in the carrier particles.

[0086] Optionally, the signals used to distinguish different particle groups are different fluorescence wavelengths and fluorescence intensities.

[0087] Optionally, the carrier particle concentration is 1×10⁻⁶. 4 More than 1×10⁻⁶ cells / mL and 1×10⁻⁶ cells / mL 9 Below 1 / mL.

[0088] Optionally, in the signal amplification step, the marker is biotinylate or tyrosine conjugated with a fluorescent dye (such as FITC, PE, APC).

[0089] Optionally, the carrier particles coated with the first capturing substance can capture one or more molecules of the substance to be detected.

[0090] Optionally, the engineered phage is derived from one of the following systems: T4 phage display system, single-stranded filamentous phage (M13) display system, λ phage display system, or T7 phage display system.

[0091] Optionally, the engineered phage is derived from the above-mentioned phage display system: single-display peroxidase engineered phage, double-display peroxidase and affinity engineered phage, and double-display peroxidase and second capture substance.

[0092] Optionally, the number of peroxidases, peroxidase-affinity agents, and peroxidase-second capture substances displayed on the bacteriophage is more than 200 and less than 800.

[0093] Optionally, the engineered phage is preferably the T4 phage display system, the affinity compound is preferably streptavidin, and the peroxidase is preferably horseradish peroxidase.

[0094] Optionally, the number of horseradish peroxidases displayed on T4 phage is 800, the number of horseradish peroxidases and streptomycin affinity molecules is 600, and the number of horseradish peroxidases and second capture substances is 500.

[0095] Optionally, the T4 phage display system specifically displays the viral streptavidin (or antibody) on the small capsid protein (SOC) of the engineered phage and horseradish peroxidase on the high antigen capsid protein (HOC). Then, the engineered phage is used to infect a bacterial suspension containing Escherichia coli, and the engineered phage is replicated and assembled in the host cell.

[0096] Optionally, the reaction substrate includes one or more of benzoyl peroxide, tert-butanol peroxide, sodium persulfate, hydrogen peroxide, peracetic acid, and sodium peroxide, and the concentration of the reaction substrate is 0.1 mM to 10 mM.

[0097] Optionally, the first preset temperature is 25–37°C;

[0098] The second preset temperature is 25–37°C;

[0099] The third preset temperature is 25-37℃;

[0100] The fourth preset temperature is 4–60℃;

[0101] The fifth preset temperature is 25–37℃;

[0102] Optionally, the substance to be tested is one of the following: antibody, small molecule compound, nucleic acid, vesicle, bacteria, virus, polypeptide, antigen or hapten;

[0103] The first capturing substance is one of an antibody, a receptor protein, a complementary nucleic acid, or an aptamer;

[0104] The second capturing substance is one of an antibody, receptor protein, complementary nucleic acid, or aptamer.

[0105] Optionally, the sample to be tested is one of plasma, serum, whole blood, peripheral blood, cerebrospinal fluid, urine, environmental samples, etc.

[0106] In this invention, the detection method for low-abundance analytes (<0.1 pg / mL) based on engineered bacteriophages involves labeling the analytes with engineered bacteriophages, binding them with tyrosine and fluorescent materials to amplify the analyte signal, and finally detecting the analyte. This invention uses engineered bacteriophages instead of natural enzymes, firstly solving the problems of low monomeric enzyme activity, low sensitivity, and difficulty in forming stable and controllable polymers inherent in natural enzymes; secondly, it solves the problems of poor stability, large batch-to-batch variation in raw materials, high cost, and difficulty in standardized and stable preparation of polymers in polymer-coupled natural enzymes. Ultimately, this achieves the goal of high enzyme activity and sensitivity, good stability, small batch-to-batch variation in raw materials, low cost, and easy standardized and stable preparation.

[0107] The above and other objects, advantages and features of the present invention will become more apparent to those skilled in the art from the following detailed description of specific embodiments of the invention in conjunction with the accompanying drawings.

[0108] Example

[0109] The present invention can be better understood from the following embodiments. However, those skilled in the art will readily understand that the specific material ratios, process conditions, and results described in the embodiments are for illustrative purposes only and should not, and will not, limit the invention as described in detail in the claims.

[0110] Example 1: Screening of magnetic microspheres coated with the first capturing antibody by particle size:

[0111] (1) Prepare magnetic microspheres with average particle sizes of 1μm, 2μm, 3μm, 4μm, 5μm, and 6μm (e.g., Figure 5 (As shown) Interleukin-6 first capture antibody: Interleukin-6 first capture antibody was coated onto magnetic microspheres using NHS ester and EDC crosslinking agent at a mass ratio of 1:10 to obtain magnetic microspheres coated with the first capture antibody;

[0112] (2) Preparation steps of interleukin-6 second capture antibody against single-display peroxidase engineered phage: Using glutaraldehyde cross-linking labeling technology, the interleukin-6 second capture antibody was labeled with engineered phage at a molar ratio of 2:1 to obtain the second capture antibody against single-display horseradish peroxidase engineered phage.

[0113] (3) Mixing and incubation steps: Mix 10 μL and 50 μL of magnetic microspheres coated with the first capture antibody, containing 0.00 pg / mL and 10.00 pg / mL of interleukin-6 and 50 μL of the second capture antibody that displays horseradish peroxidase engineered phage, respectively, and incubate at 37°C for 30 min.

[0114] (4) Elution and washing: Taking advantage of the adsorption capacity of the carrier particles, the washing step is performed 3 times, each time with 200μL PBS (with 0.05% Tween-20 added);

[0115] (5) Signal amplification: Add a mixture of 50 μL of fluorescent-tyrosamide reagent and 50 μL of H2O2, and react at 37 °C in the dark for 15 min. The fluorescent-tyrosamide reagent is a FITC-coupled tyrosamide reagent with a concentration of 200 μg / mL, and the concentration of H2O2 is 0.005 wt%.

[0116] (6) Elution and washing: Utilizing the adsorption capacity of the carrier particles, the washing step is performed 3 times, each time with 200 μL PBS (with 0.05% Tween-20 added);

[0117] (7) Fluorescence detection: The above test solution is resuspended in a centrifuge tube and detected by flow cytometer. The maximum fluorescence value of negative particles is used as the threshold. Particles with fluorescence values ​​greater than this threshold (defined as positive particles) are counted and the ratio of positive particles to all particles is calculated.

[0118] (8) Results Analysis: The correlation between particle size and the ratio of positive particles is as follows: Figure 6 As shown, the smaller the particle size, the higher the background value (0 pg / mL), and the higher the percentage of positive particles in the test sample (10 pg / mL). Figure 6 This indicates that 2μm-4μm is preferred, and 3μm is more preferred.

[0119] Example 2: Optimization of the ratio of the first capturing antibody to the magnetic microsphere coating:

[0120] (1) Prepare magnetic microspheres with a particle size of 3.0 μm and coat the first capture antibody of interleukin-6 with the antibody to magnetic microsphere mass ratio of 0.5%, 2.0%, 5.0%, 10.0%, 30.0%, and 50%. The first capture antibody of interleukin-6 is coated onto the magnetic microspheres using NHS ester and EDC crosslinking agent at a mass ratio of 1:10 to obtain magnetic microspheres coated with the first capture antibody.

[0121] (2) Preparation steps of interleukin-6 second capture antibody against horseradish peroxidase engineered phage: Using glutaraldehyde cross-linking labeling technology, the engineered phage was labeled with interleukin-6 second capture antibody at a molar ratio of 2:1 to obtain the second capture antibody against horseradish peroxidase engineered phage.

[0122] (3) Mixing and incubation steps: Mix 10 μL of magnetic microspheres coated with different proportions of the first capture antibody, 50 μL of interleukin-6 at concentrations of 0.00 pg / mL and 10.00 pg / mL, and 50 μL of the second capture antibody that displays horseradish peroxidase engineered phage with shaking and incubate at 37°C for 30 min.

[0123] (4) Elution and washing: Taking advantage of the adsorption capacity of the carrier particles, the washing step is performed 3 times, each time with 200μL PBS (with 0.05% Tween-20 added);

[0124] (5) Signal amplification: Add a mixture of 50 μL of fluorescent-tyrosamide reagent and 50 μL of H2O2, and react at 37°C in the dark for 15 min to form the test solution. The fluorescent-tyrosamide reagent is a tyrosamide reagent coupled with APC at a concentration of 200 μg / mL, and the concentration of H2O2 is 0.005 wt%.

[0125] (6) Elution and washing: Utilizing the adsorption capacity of the carrier particles, the washing step is performed 3 times, each time with 200 μL PBS (with 0.05% Tween-20 added);

[0126] (7) Fluorescence detection: The above test solution is resuspended in a centrifuge tube and detected by flow cytometer. The maximum fluorescence value of negative particles is used as the threshold. Particles with fluorescence values ​​greater than this threshold (defined as positive particles) are counted and the ratio of positive particles to all particles is calculated.

[0127] (8) Results Analysis: The correlation between the coating ratio and the signal-to-noise ratio is as follows: Figure 7 As shown, both excessively low and excessively high coating ratios will reduce the signal-to-noise ratio, preferably 1%-3%, and more preferably 2%.

[0128] Example 3 demonstrates the optimization of the ratio of horseradish peroxidase-engineered phage-labeled second capture antibody:

[0129] (1) Prepare magnetic microspheres with a particle size of 3.0 μm and coat the first capture antibody of interleukin-6 with the mass ratio of antibody to magnetic microspheres of 2.0%. The first capture antibody of interleukin-6 is coated onto the magnetic microspheres with NHS ester and EDC crosslinking agent at a mass ratio of 1:10 to obtain magnetic microspheres coated with the first capture antibody.

[0130] (2) Preparation steps of interleukin-6 second capture antibody labeled with horseradish peroxidase engineered phage: Using glutaraldehyde cross-linking labeling technology, the interleukin-6 second capture antibody was labeled with engineered phage at molar ratios of 1:1, 2:1, 3:1, 4:1, 5:1, and 6:1 to obtain the second capture antibody labeled with horseradish peroxidase engineered phage.

[0131] (3) Mixing and incubation steps: Mix 10 μL of magnetic microspheres coated with different proportions of the first capture antibody, 50 μL of interleukin-6 at concentrations of 0.00 pg / mL and 10.00 pg / mL, and 50 μL of the second capture antibody that displays horseradish peroxidase engineered phage with shaking and incubate at 37°C for 30 min.

[0132] (4) Elution and washing: Taking advantage of the adsorption capacity of the carrier particles, the washing step is performed 3 times, each time with 200μL PBS (with 0.05% Tween-20 added);

[0133] (5) Signal amplification: Add a mixture of 50 μL of fluorescent-tyrosamide reagent and 50 μL of H2O2, and react at 37°C in the dark for 15 min to form the test solution. The fluorescent-tyrosamide reagent is a FITC-coupled tyrosamide reagent with a concentration of 200 μg / mL, and the concentration of H2O2 is 0.005 wt%.

[0134] (6) Elution and washing: Utilizing the adsorption capacity of the carrier particles, the washing step is performed 3 times, each time with 200 μL PBS (with 0.05% Tween-20 added);

[0135] (7) Fluorescence detection: The above test solution is resuspended in a centrifuge tube and detected by flow cytometer. The maximum fluorescence value of negative particles is used as the threshold. Particles with fluorescence values ​​greater than this threshold (defined as positive particles) are counted and the ratio of positive particles to all particles is calculated.

[0136] (8) Results Analysis: The correlation between the labeling ratio of horseradish peroxidase-engineered phage-labeled second capture antibody and the positive particle ratio is shown in the figure below. Figure 8 As shown, when the labeling ratio is greater than 1:30, the proportion of positive particles will rise rapidly. However, if the amount of labeling enzyme is too high, it will lead to an excessive number of activated tyrosine molecules, resulting in an increase in false positive particles (i.e., background) and a deterioration in the signal-to-noise ratio. The preferred ratio is 1:1-3:1, more preferably 1:1-2:1, and even more preferably 2:1.

[0137] Example 4: Determination of the stability of natural horseradish peroxidase polymer (hereinafter referred to as natural enzyme polymer) and engineered bacteriophage:

[0138] (1) Preparation steps of carrier particles coated with interleukin-6 first capture antibody: Interleukin-6 first capture antibody was coated onto 3.0 μm magnetic microspheres using NHS ester and EDC crosslinking agent at a mass ratio of 1:10 to obtain magnetic microspheres coated with the first capture antibody.

[0139] (2) Preparation steps of interleukin-6 second capture antibody against horseradish peroxidase engineered phage: Using glutaraldehyde cross-linking labeling technology, the second capture antibody of interleukin-6 was labeled with two groups of natural enzyme polymers and horseradish peroxidase engineered phage to obtain the second capture antibody of horseradish peroxidase engineered phage. Each group was divided into two parts and placed at 4℃ and 37℃ for stability testing.

[0140] (3) Mixing and incubation steps: Mix 10 μL of magnetic microspheres coated with the first capture antibody, 50 μL of interleukin-6 at concentrations of 0.00 pg / mL and 10.00 pg / mL, and 50 μL of the second capture antibody with single display of horseradish peroxide engineered phage at different time points (1 day, 3 days, 7 days, 15 days, 30 days, and 90 days) by shaking and incubate at 37°C for 30 min.

[0141] (4) Washing: Using the adsorption capacity of the magnetic microspheres, the washing step was performed 3 times, each time with 200 μL PBS (with 0.05% Tween-20 added);

[0142] (5) Signal amplification: Add a mixture of 50 μL of fluorescent-tyrosamide reagent and 50 μL of H2O2, and react at 37°C in the dark for 15 min to form the test solution. The fluorescent-tyrosamide reagent is a PE-coupled tyrosamide reagent with a concentration of 200 μg / mL, and the concentration of H2O2 is 0.005 wt%.

[0143] (6) Elution and washing: Utilizing the adsorption capacity of the carrier particles, the washing step is performed 3 times, each time with 200 μL PBS (with 0.05% Tween-20 added);

[0144] (7) Fluorescence detection: The above test solution is resuspended in a centrifuge tube and detected by flow cytometer. The maximum fluorescence value of negative particles is used as the threshold. Particles with fluorescence values ​​greater than this threshold (defined as positive particles) are counted and the ratio of positive particles to all particles is calculated.

[0145] (8) Results Analysis: The accelerated stability of natural enzyme polymers and engineered phage enzymes at 37℃ is as follows: Figure 9 As shown, the activity of natural enzyme polymers was only 13.32% after 90 days of acceleration, while the activity of engineered phage enzymes was still 59.85% after 90 days of acceleration, indicating that engineered phage enzymes have a greater advantage in stability.

[0146] Example 5 demonstrates the detection of horseradish peroxidase engineered phage sensitivity:

[0147] (1) Preparation steps of carrier particles coated with interleukin-6 first capture antibody: Interleukin-6 first capture antibody was coated onto 3μm magnetic microspheres using NHS ester and EDC crosslinking agent at a mass ratio of 1:10 to obtain magnetic microspheres coated with the first capture antibody.

[0148] (2) Preparation steps of interleukin-6 second capture antibody against horseradish peroxidase engineered phage: Using glutaraldehyde cross-linking labeling technology, the interleukin-6 second capture antibody was labeled with horseradish peroxidase engineered phage at a molar ratio of 2:1 to obtain the second capture antibody against horseradish peroxidase engineered phage.

[0149] (3) Mixing and incubation steps: Mix 10 μL and 50 μL of magnetic microspheres coated with the first capture antibody with interleukin-6 at concentrations of 0.010 pg / mL, 0.02 pg / mL, 0.20 pg / mL, 2.00 pg / mL, 20.00 pg / mL, and 100.0 pg / mL, respectively, and 50 μL of the second capture antibody that displays horseradish peroxidase engineered phage. Shake well and incubate at 37°C for 30 min.

[0150] (4) Washing: Using the adsorption capacity of the magnetic microspheres, the washing step was performed 3 times, each time with 200 μL PBS (with 0.05% Tween-20 added);

[0151] (5) Signal amplification: Add a mixture of 50 μL of fluorescent-tyrosamide reagent and 50 μL of H2O2, and react at 37°C in the dark for 15 min to form the test solution. The fluorescent-tyrosamide reagent is a PE-coupled tyrosamide reagent with a concentration of 200 μg / mL, and the concentration of H2O2 is 0.005 wt%.

[0152] (6) Elution and washing: Utilizing the adsorption capacity of the carrier particles, the washing step is performed 3 times, each time with 200 μL PBS (with 0.05% Tween-20 added);

[0153] (7) Fluorescence detection: The above test solution is resuspended in a centrifuge tube and detected by flow cytometer. The maximum fluorescence value of negative particles is used as the threshold. Particles with fluorescence values ​​greater than this threshold (defined as positive particles) are counted and the ratio of positive particles to all particles is calculated.

[0154] (8) Results analysis: According to the principle that a coefficient of variation of less than 20% can be regarded as functional sensitivity, the sensitivity of horseradish peroxidase engineered phage is shown in Table 1, and the sensitivity is 0.020 pg / mL.

[0155] Table 1 shows the detection results of horseradish peroxidase engineered bacteriophages.

[0156]

[0157] Example 6 demonstrates the detection sensitivity of horseradish peroxidase and streptavidin-engineered phages:

[0158] (1) Preparation steps of carrier particles coated with interleukin-6 first capture antibody: Interleukin-6 first capture antibody was coated onto 3μm magnetic microspheres with EDC crosslinking agent at a mass ratio of 1:10 to obtain magnetic microspheres coated with first capture antibody.

[0159] (2) Preparation steps of biotin-labeled interleukin-6 second capture antibody: Biotin was labeled with the interleukin-6 second capture antibody using the glutaraldehyde cross-linking labeling technique at a molar ratio of 2:1 to obtain the second capture antibody displaying horseradish peroxidase engineered phage.

[0160] (3) Mixing and incubation steps: Mix 10 μL of magnetic microspheres coated with the first capture antibody, 50 μL of interleukin-6 at concentrations of 0.010 pg / mL, 0.020 pg / mL, 0.200 pg / mL, 2.00 pg / mL, 20.00 pg / mL, and 100.0 pg / mL, 25 μL of biotin-labeled second capture antibody, and 25 μL of double-displayed horseradish peroxidase and streptavidin-engineered phage by shaking and incubate at 25°C for 30 min;

[0161] (4) Washing: Using the adsorption capacity of the magnetic microspheres, the washing step was performed 3 times, each time with 200 μL PBS (with 0.05% Tween-20 added);

[0162] (5) Signal amplification: Add a mixture of 50 μL of fluorescent-tyrosamide reagent and 50 μL of H2O2, and react at 25 °C in the dark for 15 min. The fluorescent-tyrosamide reagent is a FITC-coupled tyrosamide reagent with a concentration of 200 μg / mL, and the concentration of H2O2 is 0.005 wt%.

[0163] (6) Elution and washing: Utilizing the adsorption capacity of the carrier particles, the washing step is performed 3 times, each time with 200 μL PBS (with 0.05% Tween-20 added);

[0164] (7) Fluorescence detection: The above test solution is resuspended in a centrifuge tube and detected by flow cytometer. The maximum fluorescence value of negative particles is used as the threshold. Particles with fluorescence values ​​greater than this threshold (defined as positive particles) are counted and the ratio of positive particles to all particles is calculated.

[0165] (8) Results analysis: According to the principle that the coefficient of variation is less than 20%, it can be regarded as functional sensitivity. The sensitivity of double-display horseradish peroxidase and streptavidin engineered phage is shown in Table 2. The sensitivity is 0.020 pg / mL.

[0166] Table 2 shows the detection results of horseradish peroxidase and streptavidin-engineered bacteriophages.

[0167]

[0168]

[0169] Example 7 demonstrates the repeatability and sensitivity of engineered phages containing horseradish peroxidase and interleukin-6 second capture antibody:

[0170] (1) Preparation steps of carrier particles coated with interleukin-6 first capture antibody: Interleukin-6 first capture antibody was coated onto 3μm magnetic microspheres using NHS ester and EDC crosslinking agent at a mass ratio of 1:10 to obtain magnetic microspheres coated with the first capture antibody.

[0171] (2) Mixing and incubation steps: 10 μL and 50 μL of magnetic microspheres coated with the first capture antibody, containing interleukin-6 at concentrations of 0.010 pg / mL, 0.020 pg / mL, 0.200 pg / mL, 2.00 pg / mL, 20.00 pg / mL, and 100.0 pg / mL respectively, and 50 μL of engineered phage containing double-displayed horseradish peroxidase as the second capture antibody, were mixed with the interleukin-6 second capture antibody and incubated at 37°C for 30 min.

[0172] (3) Washing: Using the adsorption capacity of the magnetic microspheres, the washing step was performed 3 times, each time with 200 μL PBS (with 0.05% Tween-20 added);

[0173] (4) Signal amplification: Add a mixture of 50 μL of fluorescent-tyrosamide reagent and 50 μL of H2O2, and react at 37°C in the dark for 15 min to form the test solution. The fluorescent-tyrosamide reagent is a tyrosamide reagent coupled with APC at a concentration of 200 μg / mL, and the concentration of H2O2 is 0.005 wt%.

[0174] (5) Elution and washing: Utilizing the adsorption capacity of the carrier particles, the washing step is performed 3 times, each time with 200 μL PBS (with 0.05% Tween-20 added);

[0175] (6) Fluorescence detection: The above test solution is resuspended in a centrifuge tube and detected by flow cytometer. The maximum fluorescence value of negative particles is used as the threshold. Particles with fluorescence values ​​greater than this threshold (defined as positive particles) are counted and the ratio of positive particles to all particles is calculated.

[0176] (7) Results analysis: According to the principle that a coefficient of variation of less than 20% can be regarded as functional sensitivity, the sensitivity of the engineered phage with double-display horseradish peroxidase and interleukin-6 second capture antibody is shown in Table 3, and the sensitivity is 0.020 pg / mL.

[0177] Table 3 shows the results of horseradish peroxidase and interleukin-6 second capture antibody-engineered phages.

[0178]

[0179] Example 8: Detection of low abundance items (p-Tau 217):

[0180] (1) Preparation steps of carrier particles coated with phosphorylated Tau 217 protein first capture antibody: NHS ester and EDC crosslinking agent are used to coat the carrier particles with phosphorylated Tau 217 protein first capture antibody at a mass ratio of 1:10 to obtain carrier particles coated with first capture antibody.

[0181] (2) Preparation steps of the second capture antibody for phosphorylated Tau 217 protein of single-display horseradish peroxidase engineered phage: Using glutaraldehyde cross-linking labeling technology, the second capture antibody for phosphorylated Tau 217 protein is labeled with single-display horseradish peroxidase engineered phage at a molar ratio of 2:1 to obtain the second capture antibody for single-display horseradish peroxidase engineered phage.

[0182] (3) Mixing and incubation steps: 10 μL and 50 μL of phosphorylated Tau217 protein antigen with concentrations of 0.020 pg / mL, 0.100 pg / mL, 1.00 pg / mL, 5.00 pg / mL, 25.00 pg / mL and 75.00 pg / mL respectively, coated with the first capture antibody, and 50 μL of the second capture antibody displaying horseradish peroxidase engineered phage were shaken and mixed, and incubated at 40℃ for 30 min;

[0183] (4) Elution and washing: Taking advantage of the adsorption capacity of the carrier particles, the washing step is performed 3 times, each time with 200μL PBS (with 0.05% Tween-20 added);

[0184] (5) Signal amplification: Add a mixture of 50 μL biotin-tyrosamide reagent and 50 μL H2O2, and react at 25 °C in the dark for 15 min. The biotin-tyrosamide reagent is a reagent with a concentration of 200 μg / mL, and the concentration of H2O2 is 0.005 wt%.

[0185] (6) Elution and washing: Utilizing the adsorption capacity of the carrier particles, the washing step is performed 3 times, each time with 200 μL PBS (with 0.05% Tween-20 added);

[0186] (7) Fluorescent labeling: Add 200 μL of streptavidin-conjugated FITC and react at 37 °C in the dark for 30 min.

[0187] (8) Elution and washing: Utilizing the adsorption capacity of the carrier particles, the washing step is performed 3 times, each time with 200 μL PBS (with 0.05% Tween-20 added);

[0188] (9) Fluorescence detection: The sensitivity was determined according to the principle that a coefficient of variation of less than 20% can be considered as functional sensitivity. The sensitivity of horseradish peroxidase engineered phage in phosphorylated Tau 217 protein is shown in Table 4, with a sensitivity of 0.100 pg / mL.

[0189] Table 4 shows the results of detecting phosphorylated Tau 217 protein using horseradish peroxidase engineered phage.

[0190]

[0191]

[0192] Example 9: Detection of low-abundance items (phosphorylated Tau 181 protein):

[0193] (1) Preparation steps of carrier particles coated with phosphorylated Tau 181 protein first capture antibody: NHS ester and EDC crosslinking agent are used to coat the carrier particles with phosphorylated Tau 181 protein first capture antibody at a mass ratio of 1:10 to obtain carrier particles coated with the first capture antibody.

[0194] (2) Preparation steps of biotin-labeled phosphorylated Tau 181 protein second capture antibody: Biotin was labeled with phosphorylated Tau 181 protein second capture antibody using glutaraldehyde cross-linking labeling technology at a molar ratio of 2:1 to obtain a second capture antibody displaying horseradish peroxidase engineered phage;

[0195] (3) Mixing and incubation steps: 10 μL and 50 μL of phosphorylated Tau181 protein antigen with concentrations of 0.020 pg / mL, 0.100 pg / mL, 1.00 pg / mL, 5.00 pg / mL, 25.00 pg / mL and 75.00 pg / mL respectively, 25 μL of biotin-labeled second capture antibody, and 25 μL of double-displayed horseradish peroxidase and streptavidin-engineered phage were shaken and mixed, and incubated at 25°C for 30 min;

[0196] (4) Elution and washing: Taking advantage of the adsorption capacity of the carrier particles, the washing step is performed 3 times, each time with 200μL PBS (with 0.05% Tween-20 added);

[0197] (5) Signal amplification: Add a mixture of 50 μL of fluorescent-tyrosamide reagent and 50 μL of H2O2, and react at 25 °C in the dark for 15 min to form the test solution. The fluorescent-tyrosamide reagent is a FITC-coupled tyrosamide reagent with a concentration of 200 μg / mL, and the concentration of H2O2 is 0.005 wt%.

[0198] (6) Elution and washing: Utilizing the adsorption capacity of the carrier particles, the washing step is performed 3 times, each time with 200 μL PBS (with 0.05% Tween-20 added);

[0199] (7) Fluorescence detection: The sensitivity was determined according to the principle that a coefficient of variation of less than 20% can be considered as functional sensitivity. The sensitivity of double-display horseradish peroxidase and streptavidin engineered phage in phosphorylated Tau 181 protein is shown in Table 5. The sensitivity is 0.100 pg / mL.

[0200] Table 5 shows the results of horseradish peroxidase and streptavidin-engineered phage detection of phosphorylated Tau 181 protein.

[0201]

[0202] Example 10 Linearity Test:

[0203] (1) Preparation steps of carrier particles coated with phosphorylated Tau 217 protein first capture antibody: The phosphorylated Tau 217 protein first capture antibody was coated onto 3μm magnetic microspheres with EDC crosslinking agent at a mass ratio of 1:10 to obtain magnetic microspheres coated with the first capture antibody;

[0204] (2) Preparation steps of biotin-labeled phosphorylated Tau 217 protein second capture antibody: Biotin was labeled with phosphorylated Tau 217 protein second capture antibody using glutaraldehyde cross-linking labeling technology at a molar ratio of 2:1 to obtain a second capture antibody displaying horseradish peroxidase engineered phage;

[0205] (3) Sample preparation: Dilute the high-concentration sample and the low-concentration sample to 5 concentrations (10pg / mL, 20pg / mL, 30pg / mL, 40pg / mL, 50pg / mL) according to a certain ratio. Repeat the measurement of each concentration sample 3 times, calculate the average value, and fit the average value of the measured concentration with the theoretical concentration using the least squares method to form a straight line and calculate the linear correlation coefficient r.

[0206] (4) Mixing and incubation steps: Mix 10 μL of magnetic microspheres coated with the first capture antibody, 50 μL of phosphorylated Tau 217 protein sample diluted above, 25 μL of biotin-labeled second capture antibody, and 25 μL of double-displayed horseradish peroxidase and streptavidin-engineered phage by shaking and incubate at 25°C for 30 min.

[0207] (5) Washing and elution: Using the adsorption capacity of the magnetic microspheres, the washing step was performed three times, each time with 200 μL PBS (with 0.05% Tween-20 added);

[0208] (6) Signal amplification: Add a mixture of 50 μL of fluorescent-tyrosamide reagent and 50 μL of H2O2, and react at 25 °C in the dark for 15 min. The fluorescent-tyrosamide reagent is a PE-coupled tyrosamide reagent with a concentration of 200 μg / mL, and the concentration of H2O2 is 0.005 wt%.

[0209] (7) Elution and washing: Taking advantage of the adsorption capacity of the carrier particles, the washing step is performed 3 times, each time with 200 μL PBS (with 0.05% Tween-20 added);

[0210] (8) Fluorescence detection: The above test solution is resuspended in a centrifuge tube and detected by flow cytometer. The maximum fluorescence value of negative particles is used as the threshold. Particles with fluorescence values ​​greater than this threshold (defined as positive particles) are counted and the ratio of positive particles to all particles is calculated.

[0211] (9) Results Analysis: The linear correlation curve is as follows Figure 10 As shown, the linear regression equation is y = 0.9975x + 0.3098, R0 2 =0.9997, indicating a good linear relationship.

[0212] Example 11 demonstrates the determination of inter-batch precision of horseradish peroxidase-streptavidin engineered phages and natural horseradish peroxidase polymers coupled with streptavidin:

[0213] (1) Preparation steps of carrier particles coated with the first capture antibody of acidified Tau 217 protein: The first capture antibody of phosphorylated Tau 217 protein was coated onto 3μm magnetic microspheres with EDC crosslinking agent at a mass ratio of 1:10 to obtain magnetic microspheres coated with the first capture antibody;

[0214] (2) Preparation steps of biotin-labeled acidified Tau 217 protein second capture antibody: Biotin was labeled with phosphorylated Tau 217 protein second capture antibody using glutaraldehyde cross-linking labeling technology at a molar ratio of 2:1 to obtain a second capture antibody displaying horseradish peroxidase engineered phage;

[0215] (3) Mixing and incubation steps: Mix 10 μL of magnetic microspheres coated with the first capture antibody, 50 μL of acidified Tau 217 protein antigen with concentrations of 8.00 pg / mL (quality control 1) and 20.0 pg / mL (quality control 2) respectively, 25 μL of biotin-labeled second capture antibody, and 25 μL of different batches of double-displayed horseradish peroxidase and streptavidin-engineered phage or natural horseradish peroxidase polymer coupled with streptavidin. Shake well and incubate at 25°C for 30 min.

[0216] (4) Washing: Using the adsorption capacity of the magnetic microspheres, the washing step was performed 3 times, each time with 200 μL PBS (with 0.05% Tween-20 added);

[0217] (5) Signal amplification: Add a mixture of 50 μL of fluorescent-tyrosamide reagent and 50 μL of H2O2, and react at 25 °C in the dark for 15 min. The fluorescent-tyrosamide reagent is a FITC-coupled tyrosamide reagent with a concentration of 200 μg / mL, and the concentration of H2O2 is 0.005 wt%.

[0218] (6) Elution and washing: Utilizing the adsorption capacity of the carrier particles, the washing step is performed 3 times, each time with 200 μL PBS (with 0.05% Tween-20 added);

[0219] (7) Fluorescence detection: The above test solution is resuspended in a centrifuge tube and detected by flow cytometer. The maximum fluorescence value of negative particles is used as the threshold. Particles with fluorescence values ​​greater than this threshold (defined as positive particles) are counted and the ratio of positive particles to all particles is calculated.

[0220] (8) Results analysis: The batch-to-batch precision of the engineered phage with double-display horseradish peroxidase and streptavidin and the natural horseradish peroxidase polymer coupled with streptavidin are shown in Tables 6 and 7. The batch-to-batch precision of the engineered phage with double-display horseradish peroxidase and streptavidin is less than 6%, while that of the natural horseradish peroxidase polymer coupled with streptavidin is greater than 17%.

[0221] Table 6 shows the batch-to-batch precision of horseradish peroxidase and streptavidin-engineered phages.

[0222]

[0223] Table 7. Interbatch precision of natural horseradish peroxidase polymers coupled with streptavidin.

[0224]

[0225] Comparative Example 1: Detection of the natural monomeric enzyme interleukin-6:

[0226] (1) Preparation steps of carrier particles coated with interleukin-6 first capture antibody: Interleukin-6 first capture antibody was coated onto 3μm magnetic microspheres with EDC crosslinking agent at a mass ratio of 1:10 to obtain magnetic microspheres coated with first capture antibody.

[0227] (2) Preparation steps of biotin-labeled interleukin-6 second capture antibody: Biotin was labeled with the interleukin-6 second capture antibody using the glutaraldehyde cross-linking labeling technique at a molar ratio of 2:1 to obtain the second capture antibody displaying horseradish peroxidase engineered phage.

[0228] (3) Mixing and incubation steps: Mix 10 μL of magnetic microspheres coated with the first capture antibody, 50 μL of interleukin-6 at concentrations of 0.02 pg / mL, 0.20 pg / mL, 2.00 pg / mL, 20.00 pg / mL, 100.0 pg / mL, and 200.0 pg / mL, and 50 μL of biotin-labeled second capture antibody, shake well, and incubate at 37°C for 30 min;

[0229] (4) Washing: Using the adsorption capacity of the magnetic microspheres, the washing step was performed 3 times, each time with 200 μL PBS (with 0.05% Tween-20 added);

[0230] (5) Mixing and incubation steps: Add 50 μL of streptavidin-coupled natural monomeric enzyme solution, shake to mix, and incubate at 37°C for 30 min;

[0231] (6) Washing and elution: Using the adsorption capacity of the magnetic microspheres, the washing step was performed three times, each time with 200 μL PBS (with 0.05% Tween-20 added);

[0232] (7) Signal amplification: Add a mixture of 50 μL of fluorescent-tyrosamide reagent and 50 μL of H2O2, and react at 37 °C in the dark for 15 min. The fluorescent-tyrosamide reagent is a FITC-coupled tyrosamide reagent with a concentration of 200 μg / mL, and the concentration of H2O2 is 0.005 wt%.

[0233] (8) Elution and washing: Utilizing the adsorption capacity of the carrier particles, the washing step is performed 3 times, each time with 200 μL PBS (with 0.05% Tween-20 added);

[0234] (9) Fluorescence detection: The above test solution is resuspended in a centrifuge tube and detected by flow cytometer. The maximum fluorescence value of negative particles is used as the threshold. Particles with fluorescence values ​​greater than this threshold (defined as positive particles) are counted and the ratio of positive particles to all particles is calculated.

[0235] (10) Results analysis: According to the principle that a coefficient of variation of less than 20% can be regarded as functional sensitivity, the sensitivity of natural monomeric enzymes in interleukin-6 is shown in Table 8. The sensitivity is 2.00 pg / mL, which is 100 times different from that of engineered phages.

[0236] Table 8 Results of natural monomeric enzyme plotting for the detection of interleukin-6

[0237]

[0238]

[0239] Applying engineered phages that display functional proteins to flow cytometry digital immunoassay improves detection sensitivity and stability while reducing batch-to-batch variability. With three display methods and five reaction modes for engineered phages, the appropriate phage can be selected based on project requirements, enhancing the feasibility of the detection method.

[0240] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A flow cytometry digital immunoassay method based on engineered bacteriophages for detecting low-abundance analytes, characterized in that, Includes the following steps: S1. Preparation of carrier particles coated with the first capturing substance: coating the first capturing substance onto the carrier particles; S2. Providing a second capture substance: The second capture substance is labeled with biotin or a single-display peroxidase engineered phage to obtain a labeled second capture substance; or, the second capture substance is a double-display peroxidase and a second capture substance engineered phage; when the second capture substance is labeled with biotin, the method further includes adding a double-display peroxidase and affinity engineered phage, which binds to the biotin-labeled second capture substance through its displayed affinity; the first capture substance and the second capture substance are independently substances that specifically bind to the analyte; the engineered phage is an engineered phage that displays peroxidase on the phage coat protein using phage display technology; the number of peroxidases or double-display peroxidases and affinity displayed by the engineered phage is 200-800; S3. Binding of the analyte and the capture substance: The carrier particle coated with the first capture substance, the analyte sample, and the labeled second capture substance or double-displayed peroxidase are incubated with the second capture substance engineered phage to obtain a third binding complex; the number of peroxidases and second capture substances displayed by the engineered phage is 200-800. S4. Signal amplification: A tyrosine marker and a reaction substrate are added to the third binding complex. The reaction between the tyrosine marker and the reaction substrate is catalyzed by the peroxidase displayed by the engineered phage, thereby amplifying the signal of the analyte. After incubation, the test solution is obtained. S5. Counting analysis: Perform flow cytometry analysis on the test solution, plot a standard curve based on the test results, and calculate the content of the test substance in the test sample.

2. The method according to claim 1, characterized in that, In step S3, the binding of the analyte and the captured substance includes any one of the following a~f: a. The carrier particles coated with the first capture substance and the sample to be tested are incubated at a first preset temperature to obtain the first binding complex; the second capture substance of the labeled peroxidase engineered phage is added, shaken and mixed, and incubated at a second preset temperature to obtain the third binding complex; b. The carrier particles coated with the first capturing material, the sample to be tested, and the second capturing material of the labeled peroxidase-engineered bacteriophage are shaken and mixed, and incubated at a first preset temperature to obtain the third binding complex; c. The carrier particles coated with the first capturing substance and the sample to be tested are incubated at a first preset temperature to obtain the first binding complex; the second capturing substance labeled with biotin is added and vortexed to mix, and incubated at a second preset temperature to obtain the second binding complex; the double-display peroxidase and affinity engineered phage are added and vortexed to mix, and incubated at a third preset temperature to obtain the third binding complex. d. The carrier particles coated with the first capturing substance, the sample to be tested, the biotin-labeled second capturing substance, and the engineered phage with dual-display peroxidase and affinity are shaken and mixed, and incubated at a first preset temperature to obtain the third binding complex; e. The carrier particles coated with the first capture substance and the sample to be tested are incubated at a first preset temperature to obtain the first binding complex; the double-display peroxidase and the engineered phage of the second capture substance are added, shaken and mixed, and incubated at a second preset temperature to obtain the third binding complex. f. The carrier particles coated with the first capture substance, the sample to be tested, and the dual-display peroxidase are mixed with the engineered phage of the second capture substance by shaking and incubated at a first preset temperature to obtain the third binding complex.

3. The method according to claim 1, characterized in that, In step S4, the addition of the tyrosine marker and the reaction substrate includes any one of the following: A fluorescently labeled tyrosine and a reaction substrate are added to the third binding complex, and the mixture is incubated at a fourth preset temperature to obtain the test solution; or Biotinylated tyrosine and a reaction substrate were added to the third binding complex, and the mixture was incubated at a fourth preset temperature to obtain the fourth binding complex. In the fourth binding complex, a streptavidin-conjugated fluorescent label is added, and the mixture is incubated at the fifth preset temperature to obtain the test solution.

4. The method according to claim 1, characterized in that, In step S1, the coating method is selected from one of the following: NHS ester and EDC crosslinking, glutaraldehyde crosslinking, silanization, and biotin-avidin coupling; and / or The carrier particles include magnetic microspheres; and / or The particle size of the carrier particles is 1~10 μm; and / or The carrier particle concentration is 1×10⁻⁶. 4 Cells / mL ~ 1×10 9 per mL.

5. The method according to claim 1, characterized in that, In step S1, the first capturing substance is one of an antibody, a receptor protein, a complementary nucleic acid, or an aptamer; and / or The second capturing substance is one of an antibody, receptor protein, complementary nucleic acid, or aptamer.

6. The method according to claim 1, characterized in that, In step S4, the tyrosamide marker is biotinylate or tyrosamide conjugated with a fluorescent dye.

7. The method according to claim 1, characterized in that, The engineered phages are derived from one of the following systems: T4 phage display system, M13 single-stranded filamentous phage display system, λ phage display system, and T7 phage display system; and / or The engineered phage is selected from one of the following: single-display peroxidase engineered phage, double-display peroxidase and affinity engineered phage, and double-display peroxidase and second capture substance engineered phage.

8. The method according to claim 7, characterized in that, The engineered phage is a T4 phage display system, the affinity compound is streptavidin, and the peroxidase is horseradish peroxidase; and / or The T4 phage exhibits 800 horseradish peroxidases, 600 horseradish peroxidases and streptavidins, and 500 horseradish peroxidases and second capture substances.

9. The method according to claim 1, characterized in that, The reaction substrate includes one or more of benzoyl peroxide, tert-butanol peroxide, sodium persulfate, hydrogen peroxide, peracetic acid, and sodium peroxide, and the concentration of the reaction substrate is 0.1 mM to 10 mM; and / or The analyte is one of the following: antibody, small molecule compound, nucleic acid, vesicle, bacteria, virus, polypeptide, antigen or hapten; and / or The sample to be tested is one of the following: plasma, serum, whole blood, peripheral blood, cerebrospinal fluid, urine, or environmental sample.

10. The method according to claim 2, characterized in that, The first preset temperature is 25~37℃; The second preset temperature is 25~37℃; The third preset temperature is 25~37℃.

11. The method according to claim 3, characterized in that, The fourth preset temperature is 4~60℃; The fifth preset temperature is 25~37℃.

Citation Information

Patent Citations

  • Method for detecting low-abundance substance to be detected based on nano material

    CN118731341A

  • Novel recombinant bacteriophage

    JP2020005600A